Amolyt Pharma is building on its teams established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharmas portfolio includes AZP-3601, a parathyroid hormone analog for the potential treatment of hypoparathyroidism and AZP-3813, a potential treatment for acromegaly. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
For more information, visit their website https://amolytpharma.com
August, 2026
Thursday
August 26,2019
Awesome Job!
We have received your appointment and will send you a confirmation to your provided email upon approval.
Own or work here?
Claim Now!
Claim Now!
/ Per Listing
Lorem ipsum dolor sit amet, lorem sit.
Claim request is processed after verification..
